Fluoropyrimidine resistance in colon cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 4, 2002, Pages 409-416

  Gorlick, Richard ^a   Banerjee, Debabrata ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

5 fluorouracil; Cell cycle; Dihydropyrimidine dehydrogenase; Drug resistance; Fluorodeoxyuridine; Methotrexate; Thymidine phosphorylase; Thymidylate synthase; Trinotecan; Uridine monophosphate kinase

Indexed keywords

FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; PYRIMIDINE DERIVATIVE; THYMIDYLATE SYNTHASE;

APOPTOSIS; CANCER RESEARCH; CELL CYCLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; GENE MUTATION; HUMAN; MUTATION; REVIEW; ARTICLE; COLON TUMOR; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL CYCLE; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; PYRIMIDINES; THYMIDYLATE SYNTHASE;

EID: 0036685985     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.4.409     Document Type: Review

References (61)

1. Karnofsky Memorial Lecture: Ode to methotrexate
2. Drug resistance in colon cancer
3. Colorectal cancer
4. Resistance mechanisms to antimetabolites
5. Fluorinated pyrimidines
6. 5-Fluorouracil inhibits dihydrofolate reductase precursor mRNA processing and/or nuclear mRNA stability in methotrexate-resistant KB cells
7. Resistance to chemotherapeutic antimetabolites: A function of salvage pathway involvement and cellular response to DNA damage
8. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
9. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines
10. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
11. Thymidylate synthase overproduction gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy
12. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
13. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial
14. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
15. The role of thymidylate synythase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
16. A new prognostic factor for colorectal carcinoma, thymidylate synthase and its therapeutic significance
17. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal response and resistance to protracted infusion of fluorouracil and weekly leucovorin
18. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
19. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy
20. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared to hepatic metastases of colorectal adenocarcinoma
21. Thymidylate synthase protein expression in advanced colon cancer: Correlation with the sites of metastasis and the clinical response to leucavorin-modulated bolus 5-fluorouracil
22. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase
23. Identification of an RNA binding site for human thymidylate synthase
24. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation
25. Tymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
26. Restoration of wild type p53 activity in p53-null HL-60 cells confers multidrug sensitivity
27. p53 status and the efficacy of cancer therapy in vivo
28. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53
29. Wild type p53 restores cell cycle control and inhibits gene amplification in cells without mutant p53 alleles
30. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia and is correlated with p53 gene mutations
31. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation
32. Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells
33. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
34. Increased incidence of p53 mutations is associated with hepatic metastases in colorectal neoplastic progression
35. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis
36. p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases
37. Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylare synthase expression receiving a bolus 5-fluorouracil-leucovorin combination
38. E2F. A link between the Rb tumor suppressor protein and viral oncoproteins
39. Intrinsic and acquired resistance to methotrexate in acute leukemia
40. The regulation of E2F by pRB-family proteins
41. The E2F transcription factors: Key regulators of cell proliferation
42. 1S-regulatory genes
43. Role of E2F-1 in chemosensitivity
44. Thymidylate synthase expression correlates closely with E21F1 expression in colon cancer
45. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell lines
46. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines
47. Decreased folylpolyglutamate synthetase expression: A novel mechanism of fluorouracil resistance
48. Defective facilitated diffusion of nucleotides, a primary mechanism of resistance to 5-fluoro-2′-deoxyuridine in the HCT-8 human carcinoma
49. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules
50. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines
51. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
52. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy
53. High basal level gene expression of thymidine phosphorylase (platelet derived endothelial growth factor) in colorectal tumors is associated with non-response to 5-fluorouracil
54. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase
55. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
56. Clinical activity and benefit of irinotecan (CPT- 11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
57. High thymidylate synthase (TS) expression does not preclude activity of CPT-11 in colorectal cancer (CRC)
58. Development of a retroviral construct containing a human mutated dhfr cDNA for hematopoietic stem cell transduction
59. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA
60. Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer